Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mesalazine Clear all
Completed Phase 2 Interventional Results available

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

NCT01327300
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mesalamine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Results available

Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)

NCT00446849
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX Mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 1:04 PM EDT
Active, not recruiting Phase 4 Interventional

Determination of the Optimal Treatment Target in Ulcerative Colitis

NCT04259138
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients

NCT00069498
View directory record Official record
Conditions
HIV Infections
Interventions
5-aminosalicylic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Sep 2, 2026, 1:04 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial

NCT04095663
View directory record Official record
Conditions
Diverticulitis
Interventions
Partial Colectomy, Medical Management
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

NCT01860963
View directory record Official record
Conditions
Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions
Anal Pap smear and HPV DNA testing
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Results available

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

NCT01177410
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Recurrence of Diverticulitis

NCT00545103
View directory record Official record
Conditions
Diverticulitis
Interventions
SPD476, MMX™ mesalazine, 1.2g extended release tablet, SPD476, MMX™ mesalazine, 2.4g extended release tablet, SPD476, MMX™ mesalazine, 4.8g extended release tablet, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01402947
View directory record Official record
Conditions
Healthy
Interventions
Ciprofloxacin XR + MMX Placebo, MMX Mesalazine/mesalamine + Ciprofloxacin XR
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Recurrence of Diverticulitis

NCT00545740
View directory record Official record
Conditions
Diverticulitis
Interventions
SPD476 (1.2g), SPD476 (2.4 g), SPD476 (4.8 g), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
46
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Anaheim, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 2Phase 3 Interventional

Trial of Mesalamine for the Treatment of Active Microscopic Colitis

NCT00952952
View directory record Official record
Conditions
Microscopic Colitis, Diarrhea
Interventions
Mesalamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

NCT02522767
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
18
States / cities
Little Rock, Arkansas • Murrieta, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 2, 2026, 1:04 PM EDT
Terminated Phase 3 Interventional Results available

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

NCT01004185
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 400 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
5 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT00505778
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine Once-Daily, Mesalamine Twice-Daily
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
233
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Not applicable Interventional Results available

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

NCT01577966
View directory record Official record
Conditions
Brain Tumor
Interventions
Sulfasalazine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Sep 2, 2026, 1:04 PM EDT
Terminated Phase 3 Interventional

Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis

NCT01038739
View directory record Official record
Conditions
Diverticulitis
Interventions
Mesalazine, Placebo
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Smyrna Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 2, 2026, 1:04 PM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 2, 2026, 1:04 PM EDT
Withdrawn Phase 2 Interventional

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

NCT00514982
View directory record Official record
Conditions
Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions
Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis

NCT00408174
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Balsalazide disodium
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
88
States / cities
Tempe, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

NCT00679432
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg
Procedure · Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 2, 2026, 1:04 PM EDT
Active, not recruiting Not applicable Interventional

Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis

NCT05213234
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Chronotherapy
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 2, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis

NCT00151892
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SPD476, Asacol
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Bristol, Connecticut • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 2, 2026, 1:04 PM EDT
Not listed Phase 2 Interventional

Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01586533
View directory record Official record
Conditions
Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis
Interventions
Zoenasa-1:4, Mesalamine Enema
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Lakewood, Colorado + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 2, 2026, 1:04 PM EDT